Q3 2012 · —
Revenue$210.08M$210.08M +3.9% vs Q3 2011−0.0% vs Q2 2012
Net Income$13.21M$13.21M +17.5% vs Q3 2011+55.2% vs Q2 2012
EPS Diluted$0.46$0.46 +17.9% vs Q3 2011+53.3% vs Q2 2012
Gross Profit$130,536,000+5.7%
Operating Income$19,736,000+7.9%
Operating Cash Flowderived$27,909,000+17.3%
Free Cash Flowderived$8,192,000−29.1%
Margins · derived
Gross margin62.1%+1.0 pt vs Q3 2011
Operating margin9.4%+0.3 pt vs Q3 2011
Net margin6.3%+0.7 pt vs Q3 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2012 | Q3 2011 | Q3 2010 | Q3 2009 |
|---|---|---|---|---|
| Revenue | $210.08M | $202.19M | $186.64M | $172.29M |
| Net Income | $13.21M | $11.24M | $16.48M | $14.43M |
| EPS Diluted | $0.46 | $0.39 | $0.55 | $0.49 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR